المؤلفون: Grymonprez M; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium., Carnoy L; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium., Capiau A; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium., Boussery K; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium., Mehuys E; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium., De Backer TL; Department of Cardiology, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium., Steurbaut S; Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium.; Department of Hospital Pharmacy, UZ Brussel, Laarbeeklaan 101, 1090, Jette, Belgium., Lahousse L; Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.; Department of Epidemiology, Erasmus Medical Center, PO Box 2040, Rotterdam 3000, CA, The Netherlands.

المصدر: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2023 Dec 14; Vol. 9 (8), pp. 722-730.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium: Internet ISSN: 2055-6845 (Electronic) NLM ISO Abbreviation: Eur Heart J Cardiovasc Pharmacother Subsets: MEDLINE

مواضيع طبية MeSH: Atrial Fibrillation*/diagnosis , Atrial Fibrillation*/drug therapy , Atrial Fibrillation*/chemically induced , Stroke*/etiology, Humans ; Administration, Oral ; Anticoagulants/adverse effects ; ATP Binding Cassette Transporter, Subfamily B, Member 1/therapeutic use ; Cohort Studies ; Cytochrome P-450 CYP3A/drug effects ; Cytochrome P-450 CYP3A Inducers/adverse effects ; Cytochrome P-450 CYP3A Inducers/therapeutic use ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Hemorrhage/chemically induced